SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

“While AI is incredibly powerful, it can also introduce some challenges,” says Akamai

The CFO's GenAI revolution: Future proofing finance

Stanley Fischer, former Bank of Israel Governor and US Fed Vice Chair, dies at 81

Israeli AI startup REplace raises $2.1M to accelerate clean energy deployment with site selection platform

Buzz

Most popular

Daily

Weekly

1

Tenable acquires Sam Altman-backed Apex for over $105 million to boost AI security

2

Combat-ready and camera-eyed: The X-Intra drone joins Israel’s arsenal

3

Buildots raises $45M at $300M valuation to modernize global construction with AI

4

Guardicore founders raise $32 million for new stealth cyber-AI startup

5

Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive

Kare Schultz

6 stories about Kare Schultz

Closure of another criminal case will help Teva's new CEO to focus on return to growth

22.08.23|Sophie Shulman

The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations

ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Schultz kept Teva away from the abyss, but couldn't find a runway to growth

22.11.22|Sophie Shulman

Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines

מפעל טבע טק נאות חובב פיטורים

Teva in talks with Covid-19 vaccine manufacturers to co-produce shots

10.02.21|Reuters and CTech

"We are positive towards contributing by manufacturing some of those vaccines that either have been approved or are just about to be approved," said CEO

קור שולץ מנכ"ל חברת טבע תרופות 23.8.20

Teva beats analysts predictions with increased revenues from growth drivers

10.02.21|Sophie Shulman

The Israeli pharmaceutical company concluded the quarter with $4.5 billion in revenues, bringing it to a total of $16.6 billion for 2020

מנכ"ל טבע החדש קור שולץ

Generic Drugmaker Teva Says Profit Will Continue to Drop in 2018

08.02.18|Dror Reich

Israel’s Teva reports a $17-billion goodwill impairment citing the decline of the U.S. generic market

מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich

Troubled drugmaker says new CEO must work to quickly regain its financial credibility